PCV13, a pneumonia vaccine that can be given to babies

Content

References:

[1] OULDALI N, VARON E, LEVY C, et al. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study[J]. Lancet Infect Dis, 2021, 21(1): 137-147.

[2] FUJIKAWA H, MIYAZATO Y, EBISUDA K, et al. Severe Inflammatory Response in Myelodysplastic Syndrome and Trisomy 8 Following 23-Valent Polysaccharide Pneumococcal Vaccine Administration.[J]. Turk J Haematol, 2021, 38(1): 92-94.

[3] LAI X, WAHL B, YU W, et al. National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China: Modelled estimates for 2010-17[J].Lancet Reg Health West Pac, 2022, 22: 100430.

[4] Li Yan, Li Keli, Li Yuan, et al. Monitoring of suspected adverse reactions to the 13-valent pneumococcal polysaccharide conjugate vaccine in China from 2017 to 2020 [J]. China Vaccines and Immunization, 2023, 29(5): 578-583.

Link
http://mp.weixin.qq.com/s?__biz=MzA3NzcyNDk0Mg==&mid=2651152770&idx=1&sn=22c1b5ef5226d96c667a8947253b84da&chksm=85b10aadab0827c1ad4d1f6ec2644a81b298262c91f390b84c7980823394f7c99b70201d7bc7&scene=126&sessionid=1744614375#rd
Summary
The referenced articles focus on various aspects of pneumococcal disease and vaccination. Ouldali et al. (2021) conducted a 17-year national surveillance study in France, analyzing the incidence of invasive pneumococcal disease in children and adults during the pneumococcal conjugate vaccine era, revealing significant trends. Fujikawa et al. (2021) reported a severe inflammatory response in a patient with myelodysplastic syndrome and trisomy 8 following the administration of the 23-valent polysaccharide pneumococcal vaccine, highlighting potential adverse effects. Lai et al. (2022) provided modeled estimates of the disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children across China from 2010 to 2017, emphasizing the public health impact of these pathogens. Lastly, a study by Li et al. (2023) monitored suspected adverse reactions to the 13-valent pneumococcal conjugate vaccine in China from 2017 to 2020, contributing to the understanding of vaccine safety. Collectively, these studies underscore the importance of vaccination in controlling pneumococcal disease while also addressing safety concerns and disease burden in different populations.